Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL (O-ICE)
Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Jessica Hochberg, MD
- Phone Number: 914-594-2150
- Email: jessica_hochberg@nymc.edu
Study Contact Backup
- Name: Mitchell Cairo, MD
- Phone Number: 914-594-2150
- Email: mitchell_cairo@nymc.edu
Study Locations
-
-
New York
-
Valhalla, New York, United States, 10595
- Recruiting
- New York Medical College
-
Contact:
- Jessica Hochberg, MD
- Phone Number: 914-594-2150
- Email: jessica_hochberg@nymc.edu
-
Contact:
- Mitchell Cairo, MD
- Phone Number: 914-594-2150
- Email: mitchell_cairo@nymc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including:
- Diffuse Large B-Cell Lymphoma
- Burkitt Lymphoma
- High Grade B-cell Lymphoma: Not Otherwise Specified (NOS)
- Primary mediastinal B-cell lymphoma (PMBL)
- CD20+ B-lymphoblastic lymphoma
- Follicular lymphoma, Grade III
- Karnofsky ≥ 60% for patients > 16 years of age and
- Lansky ≥ 60 for patients ≤ 16 years of age.
- Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study.
- Patients may not have received prior therapy with obinutuzumab (GA101)
- Radiation Therapy (XRT): Date of receiving prior XRT must be > 2 weeks for local palliative XRT (small port); > 6 months must have elapsed if prior craniospinal XRT or if > 50% radiation of pelvis; > 6 weeks must have elapsed if other substantial bone marrow radiation.
- Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy.
- Adequate organ function.
Exclusion Criteria:
- Patients with newly diagnosed, previously untreated B-NHL.
- Known congenital or acquired immune deficiency.
- Prior solid organ transplantation.
- Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher.
- History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies
- Uncontrolled hepatitis B and/or C infection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Central Nervous System (CNS) Negative
All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2.
Patients without CNS involvement will receive one dose of Liposomal cytarabine for CNS prophylaxis on day -13.
Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting one day prior to the Liposomal cytarabine.
Dexamethasone 0.15 mg/kg/dose (max 4mg) IV BID will be given days -14 to -10.
Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE.
O-ICE chemotherapy is given in 21-day (3-week) cycles.
Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13.
Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
|
Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
Other Names:
Will be given intrathecally for both prophylaxis and treatment of CNS disease.
Other Names:
Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
Other Names:
Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
Other Names:
Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
Other Names:
|
|
Experimental: CNS Positive
All patients will receive 4 doses of obinutuzumab on days -14, -10, -6 and -2.
Patients with positive CSF prior to enrollment will receive treatment with two doses of Liposomal cytarabine during the prephase portion of therapy.
Liposomal cytarabine will be given intrathecally on days -13 and -5.
Dexamethasone will be given for 5 days with each Liposomal cytarabine dose starting the day prior to the Liposomal cytarabine.
Dexamethasone will be given days -14 to -10 and days -6 through -2.
Following completion of the Prephase (or at the first sign of progressive disease), all patients will proceed to cycle 1 of O-ICE.
O-ICE chemotherapy is given in 21-day (3-week) cycles.
Three weekly doses of obinutuzumab will be given days -2 (during the prephase), +6 and +13.
Patients will receive ICE chemotherapy (ifosfamide-carboplatin-etoposide) administered on Days 0-2 of Cycle 1.
|
Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
Other Names:
Will be given intrathecally for both prophylaxis and treatment of CNS disease.
Other Names:
Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
Other Names:
Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
Other Names:
Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety as assessed by adverse reactions and events
Time Frame: 1 month
|
Patients will be monitored for adverse reactions and events of drug when given alone and in combination with ICE chemotherapy.
|
1 month
|
|
Response rate assessed following each treatment cycle for regression of tumor
Time Frame: 3 months
|
Patients will be assessed following each treatment cycle for regression of tumor.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Mitchell Cairo, MD, New York Medical College
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Immune System Diseases
- Infections
- Virus Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- DNA Virus Infections
- Lymphatic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphoid
- Leukemia
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Tumor Virus Infections
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Burkitt Lymphoma
- Antineoplastic Agents, Immunological
- Antineoplastic Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Etoposide
- Obinutuzumab
- Carboplatin
- Ifosfamide
Other Study ID Numbers
Other Study ID Numbers
- L-11,392
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.